X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SUVEN LIFE Fact Sheet, SUVEN LIFE Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE Fact Sheet   (SVNP)

Here is the latest financial fact sheet of SUVEN LIFE. For more details, see the SUVEN LIFE quarterly results and SUVEN LIFE share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUVEN LIFE Price History

Price Rs 189.7
Mkt Cap Rs m 22,163
Vol '000 26.7
P/E X 19.2
P/CF X 19.8
EPS (TTM) Rs 9.9
% ch % 0.2
No. of shares m 116.83
% ch week % -3.3
% ch 1-mth % -7.1
% ch 12-mth % 9.4
52 week H/L Rs 250.8/155.0
(As on Feb 23, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUVEN LIFE Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
SUVEN LIFE EQUITY SHARE DATA
High Rs263583323339 
Low Rs12142272144 
Sales per share (Unadj.) Rs17.522.143.740.939.2 
Earnings per share (Unadj.) Rs1.22.612.38.57.5 
Diluted earnings per shareRs1.22.612.39.38.1 
Cash flow per share (Unadj.) Rs1.73.313.19.58.8 
Dividends per share (Unadj.) Rs0.300.300.500.602.00 
Adj. dividends per shareRs0.300.300.500.652.18 
Dividend yield (eoy) %1.61.20.90.30.8 
Book value per share (Unadj.) Rs10.913.222.643.949.0 
Adj. book value per shareRs10.913.222.647.953.4 
Shares outstanding (eoy) m116.73116.82116.82127.28127.28 
Bonus/Rights/Conversions  -OI-IS- 
Price / Sales ratio x1.11.11.24.86.2 
Avg P/E ratio x15.19.24.323.132.4 
P/CF ratio (eoy) x10.77.44.020.827.5 
Price / Book Value ratio x1.71.82.34.54.9 
Dividend payout %24.411.44.17.026.8 
Avg Mkt Cap Rs m2,1712,8506,15625,10030,732 
No. of employees `000NANANA0.91.0 
Total wages/salary Rs m228254314365416 
Avg. sales/employee Rs ThNMNMNM5,912.15,236.1 
Avg. wages/employee Rs ThNMNMNM414.4436.5 
Avg. net profit/employee Rs ThNMNMNM1,234.4995.5 
SUVEN LIFE INCOME DATA
Net Sales Rs m2,0422,5795,1035,2094,995 
Other income Rs m19103086194 
Total revenues Rs m2,0612,5895,1335,2945,189 
Gross profit Rs m2325322,1911,5951,233 
Depreciation Rs m607988118167 
Interest Rs m991351054754 
Profit before tax Rs m913292,0271,5161,205 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m-5220586428255 
Profit after tax Rs m1443081,4421,088950 
Gross profit margin %11.320.642.930.624.7 
Effective tax rate %-57.16.128.928.221.2 
Net profit margin %7.012.028.220.919.0 
SUVEN LIFE BALANCE SHEET DATA
Current assets Rs m1,0491,3692,8064,7704,986 
Current liabilities Rs m1,0071,0741,5511,2741,042 
Net working cap to sales %2.111.424.667.179.0 
Current ratio x1.01.31.83.74.8 
Inventory Days Days8376565761 
Debtors Days Days4534472839 
Net fixed assets Rs m1,5611,6571,9212,7903,126 
Share capital Rs m117117117127127 
"Free" reserves Rs m7581,0262,1253,0743,717 
Net worth Rs m1,2751,5452,6455,5936,236 
Long term debt Rs m550642377615432 
Total assets Rs m2,8503,2764,8667,7318,079 
Interest coverage x1.93.420.333.223.2 
Debt to equity ratio x0.40.40.10.10.1 
Sales to assets ratio x0.70.81.00.70.6 
Return on assets %8.513.531.814.712.4 
Return on equity %11.320.054.519.415.2 
Return on capital %10.421.270.625.218.9 
Exports to sales %89.084.590.188.187.5 
Imports to sales %16.515.19.411.612.2 
Exports (fob) Rs m1,8182,1804,6004,5904,371 
Imports (cif) Rs m337389482602611 
Fx inflow Rs m1,8182,1804,7524,7794,666 
Fx outflow Rs m430515608855942 
Net fx Rs m1,3881,6654,1433,9243,724 
SUVEN LIFE CASH FLOW
From Operations Rs m 338 307 1,212 1,429 922 
From Investments Rs m -320 -147 -355 -1,105 -619 
From Financial Activity Rs m -18 26 -382 1,791 -698 
Net Cashflow Rs m -1 186 474 2,116 -396 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 63.4%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.0%
FIIs 0.0%
ADR/GDR 0.0%
Free float 36.5%
Shareholders 37,287
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034
E-MAIL investorservices@suven.com WEB www.suven.com
TELEPHONE (040) 2354 3311 FAX (040) 2354 1152
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Karvy & Company
COMP SEC: K. Hanumantha Rao YEAR OF INC: 1989 BSE CODE: 530239 FV (Rs): 1 DIV YIELD (%): 1.1

More Pharmaceuticals Company Fact Sheets:   DISHMAN PHARMA  AUROBINDO PHARMA  VENUS REMEDIES  FDC LTD.  ASTRAZENECA PHARMA  

Compare SUVEN LIFE With:   DISHMAN PHARMA  AUROBINDO PHARMA  VENUS REMEDIES  FDC LTD.  ASTRAZENECA PHARMA  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE

SUVEN LIFE - ADCOCK INGRAM COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS